Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Assets (2022 - 2025)

Atara Biotherapeutics (ATRA) has disclosed Assets for 4 consecutive years, with $30.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Assets fell 78.86% year-over-year to $30.2 million, compared with a TTM value of $30.2 million through Sep 2025, down 78.86%, and an annual FY2024 reading of $109.1 million, down 34.08% over the prior year.
  • Assets was $30.2 million for Q3 2025 at Atara Biotherapeutics, down from $36.9 million in the prior quarter.
  • Across five years, Assets topped out at $436.1 million in Q2 2022 and bottomed at $30.2 million in Q3 2025.
  • Average Assets over 4 years is $209.6 million, with a median of $165.5 million recorded in 2023.
  • The sharpest move saw Assets decreased 23.96% in 2023, then plummeted 78.86% in 2025.
  • Year by year, Assets stood at $376.4 million in 2022, then tumbled by 56.03% to $165.5 million in 2023, then crashed by 34.08% to $109.1 million in 2024, then tumbled by 72.35% to $30.2 million in 2025.
  • Business Quant data shows Assets for ATRA at $30.2 million in Q3 2025, $36.9 million in Q2 2025, and $62.0 million in Q1 2025.